HRS-3802
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 13, 2025
Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=100 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Monotherapy • Oncology • Solid Tumor
January 13, 2025
Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
(clinicaltrials.gov)
- P1 | N=100 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.
Monotherapy • New P1 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1